Plasmapheresis for thrombotic thrombocytopenic purpura following bone marrow transplantation.
Recognition of thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) following bone marrow transplantation (BMT) has increased in recent years. The use of plasma exchange has greatly improved the outlook of de novo TTP. Fewer data are available on its use in post-BMT TTP but small uncontrolled series showed poor results with low response rates. We present here a case of a young patient who developed manifestations of TTP 10 months after BMT with complete recovery following treatment with plasma exchange for 1 month. This case suggests that plasma exchange could be life saving and should be tried in every patient with post-BMT TTP.
Kolker
O
O
Medical Intensive Care Unit, Division of Internal Medicine, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
Sviri
S
S
Linton
D M
DM
Or
R
R
Nagler
A
A
Shapira
M Y
MY
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000633:toxicity; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology / Q000628:therapy; D006801:Humans; D007557:Israel; D008297:Male; D012516:Osteosarcoma / Q000150:complications / Q000628:therapy; D010951:Plasma Exchange; D010956:Plasmapheresis; D011697:Purpura, Thrombotic Thrombocytopenic / Q000209:etiology / Q000628:therapy*; D013997:Time Factors